Cash
Portfolio
TrendingMidtermsElectionsPoliticsSportsCultureCryptoCommoditiesClimateEconomicsMentionsFinanceTech & Science
PredictLive147AccountSocial
MARKETSPERPSLIVE147
Product
Kalshi ProPerpetual FuturesMarketsIncentive programInstitutionsAPI & developers
Company
AboutKalshi ResearchBlogCareersPolicy CenterBrand Kit
Help
Help CenterFAQFee scheduleTrading hoursRegulatoryTrust Center

© 2026 Kalshi Inc. · All rights reserved
PrivacyData Terms of ServiceTrading ProhibitionsFAQ for Finance Professionals
Trading on Kalshi involves risk and may not be appropriate for all. Members risk losing their cost to enter any transaction, including fees. You should carefully consider whether trading on Kalshi is appropriate for you in light of your investment experience and financial resources. Any trading decisions you make are solely your responsibility and at your own risk. Information is provided for convenience only on an "AS IS" basis. Past performance is not necessarily indicative of future results. Kalshi is subject to U.S. regulatory oversight by the CFTC.
Series Image
  1. Trump

Which peptides will the FDA propose adding to the 503A Bulks List?



Chance

Epitalon
79%

Epitalon

79%

KPV
72%

KPV

72%

BPC-157
71%

BPC-157

71%

4 more

Which peptides will the FDA propose adding to the 503A Bulks List?

Epitalon

Odds
80% chance
Max payout
Sep 30, 2027
$0
$1,840 vol